Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA

NCT00085189 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00085189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00085189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
September 30, 2007
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ciliary body and choroid melanoma, medium/large size, ciliary body and choroid melanoma, small size, extraocular extension melanoma, iris melanoma, metastatic intraocular melanoma, mucosal melanoma, recurrent intraocular melanoma, recurrent melanoma, stage iic melanoma, stage iiia intraocular melanoma, stage iiia melanoma, stage iiib intraocular melanoma, stage iiib melanoma, stage iiic intraocular melanoma, stage iiic melanoma, stage iv intraocular melanoma, stage iv melanoma